Antibiotics in Cutaneous Medicine: An Update

Seminars in Cutaneous Medicine and Surgery

Volumn 22, Issue 3, 2003, Pages 196-211

  Carter, Eric L ^a  

^a Herbert Irving Pavilion ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMOXICOT; AMPICILLIN; ANTIBIOTIC AGENT; BENZATHINE PENICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFALORIDINE; CEFALOTIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOXACILLIN; CORTICOSTEROID; DICLOXACILLIN; MACROLIDE; MARCILLIN; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN V; PENICILLIN V POTASSIUM; PIPERACILLIN; PROCAINE PENICILLIN; QUINOLONE DERIVATIVE; RIFAMPICIN; SULFONAMIDE; SULTAMICILLIN; TETRACYCLINE DERIVATIVE; TICARCILLIN; UNINDEXED DRUG;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE PANCREATITIS; ANAPHYLAXIS; ANTIBIOTIC THERAPY; BLOOD DYSCRASIA; DEPRESSION; DRUG ABSORPTION; DRUG INDICATION; ERYTHEMA MULTIFORME; FEVER; HEADACHE; HUMAN; HYPERKALEMIA; LIVER TOXICITY; NEPHROTOXICITY; POLYARTERITIS NODOSA; REVIEW; STEVENS JOHNSON SYNDROME;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; HUMANS; SKIN DISEASES;

EID: 0242441971     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1085-5629(03)00046-4     Document Type: Review

References (117)

1. Collart P, Poitevin M, Milovanovic A, et al: Kinetic study of serum penicillin concentrations after single doses of benzathine and benethamine penicillins in young and old people. Br J Vener Dis 56:355-362, 1980
2. Frentz G, Nielsen PB, Espersen F, et al: Penicillin concentrations in blood and spinal fluid after a single intramuscular injection of penicillin G benzathine. Eur J Clin Microbiol 3:147-149, 1984
3. Neu HC: Antistaphylococcal penicillins. Med Clin North Am 66:51-60, 1982
4. Neu HC: Beta-lactamases, beta-lactamase inhibitors, and skin and skin-structure infections. J Am Acad Dermatol 22: 896-904, 1990
5. Gilbert DN, Moellering RC, Sande MA: The Sanford Guide to Antimicrobial Therapy (ed 32). Hyde Park, VT, Antimicrobial Therapy, Inc, 2002
6. Griego RD, Rosen T, Orengo IF, et al: Dog, cat, and human bites: a review. J Am Acad Dermatol 33:1019-1029, 1995
7. Goldstein EJ: Bite wounds and infection. Clin Infect Dis 14:633-638, 1992
8. Bradley JS: Cellulitis, in Jenson HB, Baltimore RS, (eds): Pediatric Infectious Diseases: Principles and Practice (ed 2). Philadelphia, PA, Saunders, 2002, pp 578-586
9. Bigby M: Rates of cutaneous reactions to drugs. Arch Dermatol 137:765-770, 2001
10. Weary PE, Cole JW, 3rd, Hickam LH: Eruptions from ampicillin in patients with infectious mononucleosis. Arch Dermatol 101:86-91, 1970
11. Litt JZ: Drug Eruption Reference Manual (ed 9). Boca Raton, FL, Parthenon Publishing, 2003
12. Idsoe O, Guthe T, Willcox RR, et al: Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. Bull World Health Organ 38: 159-188, 1968
13. Rudolph AH, Price EV: Penicillin reactions among patients in venereal disease clinics. A national survey. JAMA 223:499-501, 1973
14. Weiss ME, Adkinson NF: Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin Allergy 18:515-540, 1988
15. Salkind AR, Cuddy PG, Foxworth JW: The rational clinical examination. Is this patient allergic to penicillin? An evidence-based analysis of the likelihood of penicillin allergy. JAMA 285:2498-2505, 2001
16. Macy E, Burchette RJ: Oral antibiotic adverse reactions after penicillin skin testing: multi-year follow-up. Allergy 57: 1151-1158, 2002
17. Anne S, Reisman RE: Risk of administering cephalosporin antibiotics to patients with histories of penicillin allergy. Ann Allergy Asthma Immunol 74:167-170, 1995
18. Petz LD: Immunologic cross-reactivity between penicillins and cephalosporins: a review. J Infect Dis 137:S74-S79, 1978 (suppl)
19. Lin RY: A perspective on penicillin allergy. Arch Intern Med 152:930-937, 1992
20. Weiss ME, Adkinson NF: Beta-Lactam Allergy, in Mandell GL, Bennett JE, Dolin R, (eds): Principles and Practice of Infectious Diseases (ed 5). New York, NY, Churchill Livingstone, 2000, pp 299-305
21. Petri WA: Penicillins, Cephalosporins, and Other Beta-Lactam Antibiotics, in Hardman JG, Limbird LK, Gilman AG, (eds): Goodman and Gilman's The Pharmacological Basis of Therapeutics (ed 10). New York, NY, McGraw-Hill, 2001, pp 1189-1218
22. Nordin K, Hallander H, Fredriksson T, et al: A clinical and bacteriological evaluation of the effect of sulphamethoxazole-trimethoprim in acne vulgaris, resistant to prior therapy with tetracyclines. Dermatologica 157:245-253, 1978
23. McNeil MM, Brown JM: The medically important aerobic actinomycetes: Epidemiology and microbiology. Clin Microbiol Rev 7:357-417, 1994
24. Ang P, Rattana-Apiromyakij N, Goh CL: Retrospective study of Mycobacterium marinum skin infections. Int J Dermatol 39:343-347, 2000
25. Margileth AM: Antibiotic therapy for cat-scratch disease: Clinical study of therapeutic outcome in 268 patients and a review of the literature. Pediatr Infect Dis J 11:474-478, 1992
26. Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 51:1-78, 2002
27. Hipolito RB, Mallorca FG, Zuniga-Macaraig ZO, et al: Head lice infestation: Single drug versus combination therapy with one percent permethrin and trimethoprim/sulfamethoxazole. Pediatrics 107:E30, 2001
28. Ioannidis JP, Cappelleri JC, Skolnik PR, et al: A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 156:177-188, 1996
29. Myers MW, Jick H: Hospitalization for serious blood and skin disorders following co-trimoxazole. Br J Clin Pharmacol 43:649-651, 1997
30. Jick H, Derby LE: A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity. Pharmacotherapy 15:428-432, 1995
31. Plewig G, Schopf E: Anti-inflammatory, effects of anti-microbial agents. J Invest Dermatol 65:532-536, 1975
32. Tarayre JP, Aliaga M, Barbara M, et al: Cutaneously applied erythromycin base reduces various types of inflammatory reactions in mouse ear. Int J Tissue React 9:77-85, 1987
33. Culic O, Erakovic V, Parnham MJ: Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 429:209-229, 2001
34. Scaglione F, Rossoni G: Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother 41:47-50, 1998 (suppl B)
35. Labro MT: Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother 41: 37-46, 1998 (suppl B)
36. Ianaro A, Ialenti A, Maffia P, et al: Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 292: 156-163, 2000
37. Gammon WR, Meyer C, Lantis S, et al: Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris. A double-blind study. J Am Acad Dermatol 14:183-186, 1986
38. Burkhart CG: Pitted keratolysis: A new form of treatment. Arch Dermatol 116:1104, 1980
39. Coates P, Vyakrnam S, Eady EA, et al: Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol 146:840-848, 2002
40. Aubry A, Chosidow O, Caumes E, et al: Sixty-three cases of Mycobacterium marinum infection: Clinical features, treatment, and antibiotic susceptibility of causative isolates, Arch Intern Med 162:1746-1752, 2002
41. Steigbigel NH: Macrolides and Clindamycin, in Mandell GL, Bennett JE, Dolin R, (eds): Principles and Practice of Infectious Diseases (ed 5). New York, NY, Churchill Livingstone, 2000, pp 366-382
42. Wasilewski MM, Wilson MG, Sides GD, et al: Comparative efficacy of 5 days of dirithromycin and 7 days of erythromycin in skin and soft tissue infections. J Antimicrob Chemother 46:255-262, 2000
43. Watkins VS, Smietana M, Conforti PM, et al: Comparison of dirithromycin and penicillin for treatment of streptococcal pharyngitis., Antimicrob Agents Chemother 41:72-75, 1997
44. Derriennic M, Escande JP: Dirithromycin in the treatment of skin and skin structure infections. J Antimicrob Chemother 31:159-168, 1993 (suppl C)
45. Truhan AP, Hebert AA, Esterly NB: Pityriasis lichenoides in children: Therapeutic response to erythromycin. J Am Acad Dermatol 15:66-70, 1986
46. Coskey RJ: Perioral dermatitis. Cutis 34:55-58, 1984
47. Jang HS, Oh CK, Cha JH, et al: Six cases of confluent and reticulated papillomatosis alleviated by various antibiotics. J Am Acad Dermatol 44:652-655, 2001
48. Fox BJ, Odom RB, Findlay RF: Erythromycin therapy in bullous pemphigoid: possible anti-inflammatory effects. J Am Acad Dermatol 7:504-510, 1982
49. Mensing H, Krausse S: Therapy of bullous pemphigoid with erythromycin. Med Klin 85:481-484, 1990
50. Sharma PK, Yadav TP, Gautam RK, et al: Erythromycin in pityriasis rosea: A double-blind, placebo-controlled clinical trial. J Am Acad Dermatol 42:241-244, 2000
51. Klempner MS, Styrt B: Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA 260:2682-2685, 1988
52. Dajani AS, Taubert KA, Wilson W, et al: Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA 277:1794-1801, 1997
53. Panzer JD, Poche W, Meek TJ, et al: Acne treatment: A comparative efficacy trial of clindamycin and tetracycline. Cutis 19:109-111, 1977
54. Christian GL, Krueger GG: Clindamycin vs placebo as adjunctive therapy in moderately severe acne. Arch Dermatol 111:997-1000, 1975
55. Powell JJ, Dawber RP, Gatter K: Folliculitis decalvans including tufted folliculitis: Clinical, histological and therapeutic findings. Br J Dermatol 140:328-333, 1999
56. Scholar EM, Pratt WB: Bacteriostatic inhibitors of protein synthesis: The Antimicrobial Drugs (ed 2). Oxford pp 159-210, Oxford University Press, 2000
57. Amin AR, Attur MG, Thakker GD, et al: A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases. Proc Natl Acad Sci USA 93:14014-14019, 1996
58. Kuzin II, Snyder JE, Ugine GD, et al: Tetracyclines inhibit activated B cell function. Int Immunol 13:921-931, 2001
59. Uitto VJ, Firth JD, Nip L, et al: Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes. Ann N Y Acad Sci 732:140-151, 1994
60. Humbert P, Treffel P, Chapuis JF, et al: The tetracyclines in dermatology. J Am Acad Dermatol 25:691-697, 1991
61. Garner SE, Eady EA, Popescu C et al. Minocycline for acne vulgaris: Efficacy and safety. Cochrane Database Syst Rev CD002086, 2003
62. Gottlieb A: Safety of minocycline for acne. Lancet 349: 374, 1997
63. Ferner RE, Moss C: Minocycline for acne. BMJ 312:138, 1996
64. Cunliffe WJ: Minocycline for acne. Doctors should not change the way they prescribe for acne. BMJ 312:1101, 1996
65. Somech R, Arav-Boger R, Assia A, et al: Complications of minocycline therapy for acne vulgaris: Case reports and review of the literature. Pediatr Dermatol 16:469-472, 1999
66. Veien NK, Munkvad JM, Nielsen AO, et al: Topical metronidazole in the treatment of perioral dermatitis. J Am Acad Dermatol 24:258-260, 1991
67. Wormser GP, Nadelman RB, Dattwyler RJ, et al: Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. Clin Infect Dis 31:1-14, 2000 (suppl 1)
68. Inglesby TV, O'Toole T, Henderson DA, et al: Anthrax as a biological weapon, 2002: Updated recommendations for management. JAMA 287:2236-2252, 2002
69. Rate-bite fever - New Mexico, 1996. MMWR Morb Mortal Wkly Rep 47:89-91, 1998
70. Carteaud A: Un cas de papillomatose papuleuse confluente et reticulee de Gougerot et Carteaud completement blanchie par antibiotiques. Bull Soc Fr Dermatol Syphiligr 72: 396-397, 1965
71. Mortimer PS: Hidradenitis suppurativa, in Lebwohl MG, Heymann WR, Berth-Jones J, et al (eds): Treatment of Skin Diseases (ed 1). London, Mosby, 2002, pp 280-281
72. Fivenson DP, Breneman DL, Rosen GB, et al: Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 130:753-758, 1994
73. Chaffins ML, Collison D, Fivenson DP: Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: A review of 13 cases. J Am Acad Dermatol 28:998-1000, 1993
74. Amato L, Coronella G, Berti S, et al: Successful treatment with doxycycline and nicotinamide of two cases of persistent pemphigoid gestationis. J Dermatolog Treat 13:143-146, 2002
75. Bachelez H, Senet P, Cadranel J, et al: The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 137: 69-73, 2001
76. Loo WJ, P DR: Dissecting cellulitis of the scalp and folliculitis decalvans, in Lebwohl MG, Heymann WR, Berth-Jones J, et al (eds): Treatment of Skin Diseases (ed 1). London, Mosby, 2002, pp 169-173
77. Perkins W: Acne keloidalis nuchae, in Lebwohl MG, Heymann WR, Berth-Jones J, et al (eds): Treatment of Skin Diseases (ed 1). London, Mosby, 2002, pp 169-173
78. Chow RK, Ho VC: Treatment of pyoderma gangrenosum. J Am Acad Dermatol 34:1047-1-60, 1996
79. Frost P, Weinstein GD, Gomez EC: Phototoxic potential of minocycline and doxycycline. Arch Dermatol 105:681-683, 1972
80. Dubin DB, Barba AR, Sober AJ: Drug-Induced or -Related Pigmentation, in Nordlund JJ, Boissy RE, Hearing VJ, et al (eds): The Pigmentary System: Physiology and Pathophysiology. New York, NY, Oxford University Press, 1998, pp 915-935
81. Lawrenson RA, Seaman HE, Sundstrom A, et al: Liver damage associated with minocycline use in acne: A systematic review of the published literature and pharmacovigilance data. Drug Safe 23:333-349, 2000
82. Lawson TM, Amos N, Bulgen D, et al: Minocycline-induced lupus: Clinical features and response to rechallenge. Rheumatology (Oxford) 40:329-335, 2001
83. Schlienger RG, Bircher AJ, Meier CR: Minocycline-induced lupus. A systematic review. Dermatology 200:223-231, 2000
84. Dunphy J, Oliver M, Rands AL, et al: Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. Br J Dermatol 142:461-467, 2000
85. Sturkenboom MC, Meier CR, Jick H, et al: Minocycline and lupuslike syndrome in acne patients. Arch Intern Med 159:493-497, 1999
86. Finch RG: Tetracyclines, in O'Grady F, Finch RG, Lambert HP, et al (eds): Antibiotic and Chemotherapy. New York, NY, Churchill Livingstone, 1997, pp 469-484
87. Standiford HC: Tetracyclines and Chloramphenicol, in Mandell GL, Bennett JE, Dolin R, (eds): Principles and Practice of Infectious Diseases (ed 5). New York, NY, Churchill Livingstone, 2000, pp 336-348
88. Dickinson BD, Altman RD, Nielsen NH, et al: Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 98:853-60, 2001
89. ACOG Practice Bulletin: The use of hormonal contraception in women with coexisting medical conditions. Number 18, July 2000. Int J Gynaecol Obstet 75:93-106, 2001
90. Archer JS, Archer DF: Oral contraceptive efficacy and antibiotic interaction: A myth debunked. J Am Acad Dermatol 46:917-923, 2002
91. Lipsky BA, Baker CA: Fluoroquinolone toxicity profiles: A review focusing on newer agents. Clin Infect Dis 28: 352-364, 1999
92. Burkhardt JE, Walterspiel JN, Schaad UB: Quinolone arthropathy in animals versus children. Clin Infect Dis 25: 1196-1204, 1997
93. Redmond AO: Risk-benefit experience of ciprofloxacin use in pediatric patients in the United Kingdom. Pediatr Infect Dis J 16:147-149discussion 160-162, 1997
94. Hampel B, Hullmann R, Schmidt H: Ciprofloxacin in pediatric: Worldwide clinical experience based on compassionate use-safety report. Pediatr Infect Dis J 16:127-129; discussion 160-162, 1997
95. Yee CL, Duffy C, Gerbino PG, et al: Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J 21:525-529, 2002
96. Ghent CN, Carruthers SG: Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 94:488-493, 1988
97. Podesta A, Lopez P, Terg R, et al: Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 36:216-220, 1991
98. Koren G, Pastuszak A, Ito S: Drugs in pregnancy. N Engl J Med 338:1128-1137, 1998
99. Reed BR: Dermatologic drugs during pregnancy and lactation, in Wolverton SE, (ed): Comprehensive Dermatologic Drug Therapy. Philadelphia, PA, Saunders, 2001, pp 817-847
100. Niedyl JR: Antibiotics and other antimicrobial agents in pregnancy, in Yankowitz J, (ed): Drug Therapy in Pregnancy (ed 3). Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 21-31
101. Garbis H, Reuvers M, van Tonningen MR: Anti-infective agents, in Schaefer C, (ed): Drugs During Pregnancy and Lactation. Amsterdam, Elsevier, 2001, pp 58-84
102. Briggs GR, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk (ed 6). Baltimore, MD, Lippincott Williams & Wilkins, 2002
103. McCormack WM, George H, Donner A, et al: Hepatotoxicity of erythromycin estolate during pregnancy. Antimicrob Agents Chemother 12:630-635, 1977
104. Transfer of drugs and other chemicals into human milk. Pediatrics 108:776-789, 2001
105. Stockton DL, Paller AS: Drug administration to the pregnant or lactating woman: A reference guide for dermatologists. J Am Acad Dermatol 23:87-103, 1990
106. Halpern AC, Leyden JJ, Dzubow LM, et al: The incidence of bacteremia in skin surgery of the head and neck. J Am Acad Dermatol 19:112-116, 1988
107. Maurice PD, Parker S, Azadian BS, et al: Minor skin surgery. Are prophylactic antibiotics ever needed for curettage? Acta Derm Venereol 71:267-268, 1991
108. Sabetta JB, Zitelli JA: The incidence of bacteremia during skin surgery. Arch Dermatol 123:213-215, 1987
109. Carmichael AJ, Flanagan PG, Holt PJ, et al: The occurrence of bacteraemia with skin surgery. Br J Dermatol 134:120-122, 1996
110. Haas AF, Grekin RC: Antibiotic prophylaxis in dermatologic surgery. J Am Acad Dermatol 32:155-176quiz 177-180, 1995
111. George PM: Case against antibiotic prophylaxis for endocarditis and prosthesis infection in dermatologic procedures involving uninfected skin. J Am Acad Dermatol 34:153-154, 1996
112. Deacon JM, Pagliaro AJ, Zelicof SB, et al: Prophylactic use of antibiotics for procedures after total joint replacement. J Bone Joint Surg Am 78:1755-1770, 1996
113. Friedman PM, Geronemus RG: Antibiotic prophylaxes in laser resurfacing patients. Dermatol Surg 26:695-697, 2000
114. Ross EV, Amesbury EC, Barile A, et al: Incidence of postoperative infection or positive culture after facial laser resurfacing: a pilot study, a case report, and a proposal for a rational approach to antibiotic prophylaxis. J Am Acad Dermatol 39:975-981, 1998
115. Alster TS: Against antibiotic prophylaxis for cutaneous laser resurfacing. Dermatol Surg 26:697-698, 2000
116. Walia S, Alster TS: Cutaneous CO2 laser resurfacing infection rate with and without prophylactic antibiotics. Dermatol Surg 25:857-861, 1999
117. Gaspar Z, Vinciullo C, Elliott T, et al: Antibiotic prophylaxis for full-face laser resurfacing: is it necessary? Arch Dermatol 137:313-315, 2001